vs

Side-by-side financial comparison of CANTALOUPE, INC. (CTLP) and Innoviva, Inc. (INVA). Click either name above to swap in a different company.

Innoviva, Inc. is the larger business by last-quarter revenue ($114.6M vs $78.7M, roughly 1.5× CANTALOUPE, INC.). Innoviva, Inc. runs the higher net margin — 143.2% vs -0.1%, a 143.3% gap on every dollar of revenue. On growth, Innoviva, Inc. posted the faster year-over-year revenue change (24.8% vs 6.8%). Over the past eight quarters, Innoviva, Inc.'s revenue compounded faster (21.6% CAGR vs 7.7%).

Cantaloupe, Inc., previously known as USA Technologies Inc., is an American company known for its work with ePort cashless acceptance technology running on its patented ePort Connect service, a PCI compliant services. ePort Connect wirelessly facilitates electronic payment options to consumers with credit, debit, or NFC enabled electronic wallets like Apple Pay and Google Pay while providing operators with both telemetry and machine-to-machine (M2M) services. ePort technology is primarily fou...

Innoviva, Inc. is a healthcare company specializing in the development, commercialization, and royalty management of prescription therapeutics for respiratory diseases, infectious diseases, and critical care conditions. It partners with leading global pharmaceutical firms to deliver treatments for asthma, COPD and other chronic illnesses to patients across core markets including North America and Europe.

CTLP vs INVA — Head-to-Head

Bigger by revenue
INVA
INVA
1.5× larger
INVA
$114.6M
$78.7M
CTLP
Growing faster (revenue YoY)
INVA
INVA
+18.1% gap
INVA
24.8%
6.8%
CTLP
Higher net margin
INVA
INVA
143.3% more per $
INVA
143.2%
-0.1%
CTLP
Faster 2-yr revenue CAGR
INVA
INVA
Annualised
INVA
21.6%
7.7%
CTLP

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
CTLP
CTLP
INVA
INVA
Revenue
$78.7M
$114.6M
Net Profit
$-70.0K
$164.2M
Gross Margin
66.0%
Operating Margin
2.0%
34.0%
Net Margin
-0.1%
143.2%
Revenue YoY
6.8%
24.8%
Net Profit YoY
-101.4%
707.4%
EPS (diluted)
$0.00
$2.19

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTLP
CTLP
INVA
INVA
Q4 25
$78.7M
$114.6M
Q3 25
$80.9M
$107.8M
Q2 25
$82.6M
$100.3M
Q1 25
$75.4M
$88.6M
Q4 24
$73.7M
$91.8M
Q3 24
$70.8M
$89.5M
Q2 24
$72.7M
$99.9M
Q1 24
$67.9M
$77.5M
Net Profit
CTLP
CTLP
INVA
INVA
Q4 25
$-70.0K
$164.2M
Q3 25
$-919.0K
$89.9M
Q2 25
$6.8M
$63.7M
Q1 25
$49.2M
$-46.6M
Q4 24
$5.0M
$20.3M
Q3 24
$3.6M
$1.2M
Q2 24
$2.2M
$-34.7M
Q1 24
$4.7M
$36.5M
Gross Margin
CTLP
CTLP
INVA
INVA
Q4 25
66.0%
Q3 25
70.1%
Q2 25
82.9%
Q1 25
82.7%
Q4 24
85.1%
Q3 24
81.6%
Q2 24
85.1%
Q1 24
39.6%
77.5%
Operating Margin
CTLP
CTLP
INVA
INVA
Q4 25
2.0%
34.0%
Q3 25
2.0%
32.1%
Q2 25
6.3%
48.6%
Q1 25
9.1%
46.7%
Q4 24
8.4%
47.0%
Q3 24
5.8%
48.3%
Q2 24
4.9%
54.7%
Q1 24
6.3%
33.3%
Net Margin
CTLP
CTLP
INVA
INVA
Q4 25
-0.1%
143.2%
Q3 25
-1.1%
83.4%
Q2 25
8.3%
63.5%
Q1 25
65.2%
-52.6%
Q4 24
6.7%
22.1%
Q3 24
5.0%
1.4%
Q2 24
3.0%
-34.7%
Q1 24
6.9%
47.1%
EPS (diluted)
CTLP
CTLP
INVA
INVA
Q4 25
$0.00
$2.19
Q3 25
$-0.02
$1.08
Q2 25
$0.10
$0.77
Q1 25
$0.65
$-0.74
Q4 24
$0.07
$0.43
Q3 24
$0.04
$0.02
Q2 24
$0.03
$-0.55
Q1 24
$0.06
$0.46

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTLP
CTLP
INVA
INVA
Cash + ST InvestmentsLiquidity on hand
$53.0M
$550.9M
Total DebtLower is stronger
$37.7M
Stockholders' EquityBook value
$252.5M
$1.2B
Total Assets
$381.9M
$1.6B
Debt / EquityLower = less leverage
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTLP
CTLP
INVA
INVA
Q4 25
$53.0M
$550.9M
Q3 25
$55.0M
$476.5M
Q2 25
$51.1M
$397.5M
Q1 25
$46.3M
$319.1M
Q4 24
$27.7M
$305.0M
Q3 24
$33.1M
$260.6M
Q2 24
$58.9M
$217.0M
Q1 24
$50.2M
$178.4M
Total Debt
CTLP
CTLP
INVA
INVA
Q4 25
$37.7M
Q3 25
$38.3M
Q2 25
$38.7M
Q1 25
$39.2M
Q4 24
$37.0M
Q3 24
$37.3M
Q2 24
$37.5M
Q1 24
$38.1M
Stockholders' Equity
CTLP
CTLP
INVA
INVA
Q4 25
$252.5M
$1.2B
Q3 25
$251.8M
$1.0B
Q2 25
$251.0M
$714.8M
Q1 25
$240.7M
$646.9M
Q4 24
$190.1M
$691.2M
Q3 24
$186.2M
$668.5M
Q2 24
$181.7M
$665.5M
Q1 24
$178.8M
$703.7M
Total Assets
CTLP
CTLP
INVA
INVA
Q4 25
$381.9M
$1.6B
Q3 25
$389.5M
$1.4B
Q2 25
$381.9M
$1.3B
Q1 25
$370.5M
$1.3B
Q4 24
$303.0M
$1.3B
Q3 24
$312.1M
$1.2B
Q2 24
$335.6M
$1.2B
Q1 24
$319.9M
$1.3B
Debt / Equity
CTLP
CTLP
INVA
INVA
Q4 25
0.15×
Q3 25
0.15×
Q2 25
0.15×
Q1 25
0.16×
Q4 24
0.19×
Q3 24
0.20×
Q2 24
0.21×
Q1 24
0.21×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTLP
CTLP
INVA
INVA
Operating Cash FlowLast quarter
$3.1M
$54.5M
Free Cash FlowOCF − Capex
$-614.0K
FCF MarginFCF / Revenue
-0.8%
Capex IntensityCapex / Revenue
4.8%
Cash ConversionOCF / Net Profit
0.33×
TTM Free Cash FlowTrailing 4 quarters
$25.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTLP
CTLP
INVA
INVA
Q4 25
$3.1M
$54.5M
Q3 25
$7.0M
$49.7M
Q2 25
$9.4M
$44.1M
Q1 25
$22.4M
$48.6M
Q4 24
$522.0K
$59.2M
Q3 24
$-12.0M
$48.7M
Q2 24
$14.3M
$43.7M
Q1 24
$14.7M
$37.0M
Free Cash Flow
CTLP
CTLP
INVA
INVA
Q4 25
$-614.0K
Q3 25
$3.5M
Q2 25
$4.3M
Q1 25
$18.6M
Q4 24
$-3.8M
Q3 24
$-15.8M
$48.4M
Q2 24
$8.5M
Q1 24
$11.4M
FCF Margin
CTLP
CTLP
INVA
INVA
Q4 25
-0.8%
Q3 25
4.4%
Q2 25
5.3%
Q1 25
24.6%
Q4 24
-5.1%
Q3 24
-22.3%
54.1%
Q2 24
11.7%
Q1 24
16.9%
Capex Intensity
CTLP
CTLP
INVA
INVA
Q4 25
4.8%
Q3 25
4.2%
Q2 25
6.2%
Q1 25
5.1%
Q4 24
5.8%
0.0%
Q3 24
5.4%
0.3%
Q2 24
7.9%
0.0%
Q1 24
4.8%
0.0%
Cash Conversion
CTLP
CTLP
INVA
INVA
Q4 25
0.33×
Q3 25
0.55×
Q2 25
1.38×
0.69×
Q1 25
0.46×
Q4 24
0.10×
2.91×
Q3 24
-3.36×
40.14×
Q2 24
6.47×
Q1 24
3.16×
1.01×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CTLP
CTLP

Transaction Processing$47.9M61%
Subscription Revenue$21.8M28%
Products$9.0M11%

INVA
INVA

Royalty$54.9M48%
Xacduro$32.1M28%
Giapreza$19.6M17%
Xerava$7.3M6%

Related Comparisons